α-突触核蛋白和 GBA1 在帕金森病中的分子机制。
Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
机构信息
The Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, 303 E. Chicago Ave, Ward 12-369, Chicago, IL, 60611, USA.
出版信息
Cell Tissue Res. 2018 Jul;373(1):51-60. doi: 10.1007/s00441-017-2704-y. Epub 2017 Oct 24.
Abstract
Parkinson's disease (PD) is a neurodegenerative movement disorder characterized pathologically by the presence of Lewy bodies comprised of insoluble alpha (α)-synuclein. Pathological, clinical and genetic studies demonstrate that mutations in the GBA1 gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase) that is deficient in Gaucher's disease, are important risk factors for the development of PD. The molecular mechanism for the association between these two diseases is not completely understood. We discuss several possible mechanisms that may lead to GBA1-related neuronal death and α-synuclein accumulation including disruptions in lipid metabolism, protein trafficking and impaired protein quality control mechanisms. Elucidating the mechanism between GCase and α-synuclein may provide insight into potential therapeutic pathways for PD and related synucleinopathies.
摘要
帕金森病（PD）是一种神经退行性运动障碍，其病理学特征是存在由不溶性α-突触核蛋白组成的路易体。病理、临床和遗传研究表明，编码溶酶体酶葡萄糖脑苷脂酶（GCase）的 GBA1 基因突变，该酶在戈谢病中缺乏，是 PD 发展的重要危险因素。这两种疾病之间关联的分子机制尚不完全清楚。我们讨论了几种可能的机制，这些机制可能导致与 GBA1 相关的神经元死亡和α-突触核蛋白积累，包括脂质代谢、蛋白质运输和蛋白质质量控制机制受损的中断。阐明 GCase 和α-突触核蛋白之间的机制可能为 PD 和相关的突触核蛋白病提供潜在的治疗途径。
相似文献
1
Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.α-突触核蛋白和 GBA1 在帕金森病中的分子机制。
Cell Tissue Res. 2018 Jul;373(1):51-60. doi: 10.1007/s00441-017-2704-y. Epub 2017 Oct 24.
2
Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.溶酶体运输缺陷将帕金森病与戈谢病联系起来。
Mov Disord. 2016 Nov;31(11):1610-1618. doi: 10.1002/mds.26802. Epub 2016 Sep 13.
3
Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.β-葡萄糖脑苷脂酶的激活可减少帕金森病患者中脑神经元的病理性α-突触核蛋白并恢复溶酶体功能。
J Neurosci. 2016 Jul 20;36(29):7693-706. doi: 10.1523/JNEUROSCI.0628-16.2016.
4
Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance.帕金森病：酸性葡萄糖脑苷脂酶活性与α-突触核蛋白清除
J Neurochem. 2016 Oct;139 Suppl 1:198-215. doi: 10.1111/jnc.13517. Epub 2016 Feb 10.
5
Gene Mutations in α-Synucleinopathies-Molecular Mechanisms Underlying Pathology and Their Clinical Significance.α-突触核蛋白病中的基因突变-病理基础的分子机制及其临床意义。
Int J Mol Sci. 2023 Jan 20;24(3):2044. doi: 10.3390/ijms24032044.
6
Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.酸性鞘磷脂酶抑制可改善 GBA1 功能丧失时α-突触核蛋白的积累。
Hum Mol Genet. 2018 Jun 1;27(11):1972-1988. doi: 10.1093/hmg/ddy105.
7
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.GBA1 突变：α-突触核蛋白病外泌体生物标志物的前景。
Mol Genet Metab. 2020 Feb;129(2):35-46. doi: 10.1016/j.ymgme.2019.10.006. Epub 2019 Oct 23.
8
Glucocerebrosidase dysfunction in neurodegenerative disease.神经退行性疾病中葡萄糖脑苷脂酶功能障碍。
Essays Biochem. 2021 Dec 22;65(7):873-883. doi: 10.1042/EBC20210018.
9
Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.溶酶体的功能与功能障碍：戈谢病及其与帕金森病关联的分子和细胞机制
Adv Drug Deliv Rev. 2022 Aug;187:114402. doi: 10.1016/j.addr.2022.114402. Epub 2022 Jun 25.
10
Glucocerebrosidase Activity Modulates Neuronal Susceptibility to Pathological α-Synuclein Insult.葡萄糖脑苷脂酶活性调节神经元对病理性α-突触核蛋白损伤的易感性。
Neuron. 2020 Mar 4;105(5):822-836.e7. doi: 10.1016/j.neuron.2019.12.004. Epub 2019 Dec 30.
引用本文的文献
1
Polymeric nanoparticle-mediated GBA1 gene therapy is neuroprotective in a preclinical model of Parkinson's disease.聚合物纳米颗粒介导的GBA1基因疗法在帕金森病临床前模型中具有神经保护作用。
Drug Deliv Transl Res. 2025 Aug 20. doi: 10.1007/s13346-025-01944-3.
2
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species.室周小胶质细胞对α-突触核蛋白毒性物质早期反应中，从清除到易损性的年龄依赖性进展。
Mol Neurodegener. 2025 Mar 5;20(1):26. doi: 10.1186/s13024-025-00816-1.
3
Development of selective nanomolar cyclic peptide ligands as GBA1 enzyme stabilisers.作为GBA1酶稳定剂的选择性纳摩尔环状肽配体的开发。
RSC Chem Biol. 2025 Jan 31;6(4):563-570. doi: 10.1039/d4cb00218k. eCollection 2025 Apr 2.
4
Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.帕金森病精准治疗的新视角：通向个性化医疗新突破的多维度证据
Front Aging Neurosci. 2024 Jul 4;16:1417515. doi: 10.3389/fnagi.2024.1417515. eCollection 2024.
5
The hexosamine biosynthetic pathway rescues lysosomal dysfunction in Parkinson's disease patient iPSC derived midbrain neurons.己糖胺生物合成途径挽救帕金森病患者 iPSC 衍生中脑细胞溶酶体功能障碍。
Nat Commun. 2024 Jun 19;15(1):5206. doi: 10.1038/s41467-024-49256-3.
6
2024 Alzheimer's disease facts and figures.2024 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30.
7
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice.少突胶质细胞中 GBA1 的失活会影响髓鞘形成，并在小鼠中诱导神经退行性病变特征和脂质代谢失衡。
Mol Neurodegener. 2024 Mar 7;19(1):22. doi: 10.1186/s13024-024-00713-z.
8
A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease.戈谢氏病基因敲入小鼠模型脑组织的比较生化和病理学评估
Int J Mol Sci. 2024 Feb 2;25(3):1827. doi: 10.3390/ijms25031827.
9
Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease.遗传与生化研究进展：揭示帕金森病神经退行性变的病因发病机制。
Biomolecules. 2024 Jan 5;14(1):73. doi: 10.3390/biom14010073.
10
Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy.携带 L444P 变异的阿尔法-突触核蛋白 mRNA 水平在接受酶替代治疗的携带者和戈谢病患者中发现存在依赖性。
Biomolecules. 2023 Apr 3;13(4):644. doi: 10.3390/biom13040644.
本文引用的文献
1
Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes.战胜神经退行性变：靶向常染色体隐性帕金森病基因调控的共同通路
Exp Neurol. 2017 Dec;298(Pt B):191-201. doi: 10.1016/j.expneurol.2017.04.008. Epub 2017 Apr 23.
2
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.葡糖神经酰胺合酶抑制可减轻突触核蛋白病模型中的异常情况。
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2699-2704. doi: 10.1073/pnas.1616152114. Epub 2017 Feb 21.
3
Cellular functions of LRRK2 implicate vesicular trafficking pathways in Parkinson's disease.LRRK2的细胞功能表明帕金森病中存在囊泡运输途径。
Biochem Soc Trans. 2016 Dec 15;44(6):1603-1610. doi: 10.1042/BST20160228.
4
Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.用丹曲林调节兰尼碱受体可减轻戈谢病小鼠的神经元病变表型。
Hum Mol Genet. 2016 Dec 1;25(23):5126-5141. doi: 10.1093/hmg/ddw322.
5
Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.帕金森病相关的GBA突变效应在人类细胞和果蝇模型中被分子伴侣逆转。
Sci Rep. 2016 Aug 19;6:31380. doi: 10.1038/srep31380.
6
Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.β-葡萄糖脑苷脂酶的激活可减少帕金森病患者中脑神经元的病理性α-突触核蛋白并恢复溶酶体功能。
J Neurosci. 2016 Jul 20;36(29):7693-706. doi: 10.1523/JNEUROSCI.0628-16.2016.
7
A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.一种新型葡萄糖脑苷脂酶伴侣可降低戈谢病和帕金森综合征患者诱导多能干细胞衍生的多巴胺能神经元中的α-突触核蛋白和糖脂水平。
J Neurosci. 2016 Jul 13;36(28):7441-52. doi: 10.1523/JNEUROSCI.0636-16.2016.
8
Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.葡萄糖脑苷脂酶调节帕金森病小鼠模型中的认知和运动活动。
Hum Mol Genet. 2016 Jul 1;25(13):2645-2660. doi: 10.1093/hmg/ddw124. Epub 2016 Apr 28.
9
ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons.内质网应激和自噬紊乱导致GBA-N370S帕金森病诱导多能干细胞衍生的多巴胺神经元中细胞外α-突触核蛋白升高。
Stem Cell Reports. 2016 Mar 8;6(3):342-56. doi: 10.1016/j.stemcr.2016.01.013. Epub 2016 Feb 18.
10
α-Synuclein-induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models.在人类中脑突触核蛋白病模型中，α-突触核蛋白诱导的溶酶体功能障碍是通过蛋白质运输的破坏而发生的。
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1931-6. doi: 10.1073/pnas.1520335113. Epub 2016 Feb 2.
Zotero 插件